Director and 10% Owner Buys $6.0M of Bambusa Stock at $16.00 IPO Price
BBTX sits 18% above its 52-week low of $13.6 on light trading volume (0.3× avg).
Summary
Bambusa director and 10% owner Helmut Jeggle bought 375,000 shares at $16.00 for $6.0 million on IPO closing day, alongside a routine one-for-one conversion of 4,769,701 preferred shares into common stock.
Key Events · Ownership and Investor Activity · BBTX
-
Director Buys $6.0M at IPO Price
Jeggle Helmut Wolfgang acquired 375,000 common shares at $16.00 per share for $6,000,000 in an open-market purchase on 2026-11-02.
-
Preferred Converts One-for-One
4,769,701 preferred shares (Series Seed Plus 3,135,066; Series A-1 1,473,775; Series A-2 160,860) automatically converted into common stock prior to the IPO closing, with no cash received.
-
Holdings Reach 9.26M Shares
Post-transaction indirect holdings total 9,264,301 shares, held through Salvia Investment GmbH, of which the reporting person is Managing Director with sole voting and dispositive power.
-
Priced Alongside $168.9M IPO
The $16.00 purchase price matches the IPO price set on 2026-10-30, when Bambusa priced an upsized 10,555,555-share offering raising roughly $168.9 million gross.
Analysis · BBTX · Life Sciences
A director and 10% holder put $6.0 million of real money into 375,000 shares at $16.00 — the exact IPO price set on 2026-10-30 — on the day the IPO closed. That is an open-market purchase, not an option exercise or a grant, and it lands right at the top of the stock's 52-week range. The same filing also shows 4,769,701 preferred shares converting one-for-one into common, a mechanical pre-IPO step that adds no cash and no new economics. The purchase is the story: a large holder adding at the offering price is a public vote of confidence immediately after the company raised roughly $168.9 million in its listing.
How filings like this one have moved
In the 30 days to Nov 3, 2026, 40.9% of the 1143 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BBTX was trading at $16.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $796.2M. The 52-week trading range was $13.60 to $16.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.